Avalo Therapeutics, Inc. (AVTX) Operating income 2016–2025
Avalo Therapeutics, Inc. (AVTX) annual operating income history from SEC filings — each fiscal year as reported.
-$72.9MFY2025 · since FY2016: -$16.1M → -$72.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$72.9M | -6.4% |
| FY2024 | -$68.5M | -150.5% |
| FY2023 | -$27.4M | +26.9% |
| FY2022 | -$37.4M | +54.4% |
| FY2021 | -$82.1M | -12.8% |
| FY2020 | -$72.8M | -351.4% |
| FY2019 | -$16.1M | +54.4% |
| FY2018 | -$35.4M | -354.7% |
| FY2017 | $13.9M | +186.4% |
| FY2016 | -$16.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice